Shanghai HeartCare (上海心玮医疗) Pre-IPO: A Decent Story to Sell

543 Views12 Mar 2021 09:50
We think the Captor, a stent retrieving thrombectomy device, is the main selling point of the deal given its decent efficacy and safety data and it has already been approved by the NMPA.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Ke Yan, CFA, FRM
Asia Pac IPO & Placement Research, China biotech
Aequitas Research
EquitiesEquity Capital MarketsQuantitative Analysis
Price Chart(Sign Up to Access)
analytics-chart
x